+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs

Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs

Biochemical Pharmacology 70(10): 1424-1430

MDR1 overexpression is one form of the multidrug resistance (MDR) phenotype, which can be acquired by patients initially responsive to chemotherapy. Because of the high toxicity of the inhibitors of P-glycoprotein (P-gp), the protein encoded by MDR1, attention has been focused on selective modulation of the MDR1 gene. Small interfering RNAs (siRNAs) were shown to be powerful tools for such a purpose, even when used at low concentrations (<= 20 nM) in order to avoid sequence nonspecific effects. Two siRNAs used at 20 nM were shown to lead to efficient down-regulation of MDR1 at the protein level (only ca. 20% total P-gp expression remaining) in the doxorubicin selected MCF7-R human cell line. Cell surface expression of P-gp was inhibited, leading to reversal of the drug efflux phenotype (about 40% reversal with the most efficient siRNA) and enhancement of chemosensitivity (about 35%). At the mRNA level, the down-regulation of MDR1 obtained with the most efficient siRNA increased from about 50% (5 nM siRNA) to 60% (10 or 20 nM). The advantage of using a combination of siRNAs instead of a single one has been suggested. (c) 2005 Elsevier Inc. All rights reserved.

(PDF emailed within 0-6 h: $19.90)

Accession: 012315887

Download citation: RISBibTeXText

PMID: 16214115

DOI: 10.1016/j.bcp.2005.08.007

Related references

Small interfering RNAs for reversion of MDR1/P-glycoprotein-mediated multidrug resistance in cancer cells. 2007

Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Research 63(7): 1515-1519, 2003

Screening effective sequences of small interfering RNAs targeting MDR1 gene in human gastric cancer SGC7901/VCR cells. Zhonghua Zhong Liu Za Zhi 28(3): 178-182, 2006

The reversal effect on mdr1 gene-mediated multidrug resistance in gastric cancer SGC7901/VCR cells by small interfering RNA. Jiepou Xuebao 37(1): 57-61, 2006

Circumvention of multidrug resistance by suppression of MDR1 gene expression in multidrug resistant cells. Korean Journal of Biochemistry 25(1): 29-36, 1993

Effect of differentiating agents on modulation of MDR1 gene expression in multidrug-resistant hematopoietic HL60/DNR cell line. Experimental Hematology 21(6): 779-784, 1993

S9788 modulation of P-glycoprotein- and multidrug-related protein-mediated multidrug resistance by servier 9788 in doxorubicin-resistant MCF7 cells. Biochemical Pharmacology 56(4): 497-502, Aug 15, 1998

MDR1 gene expression and differentiation of multidrug resistant K562 cells. Proceedings of the American Association for Cancer Research Annual Meeting 34(0): 316, 1993

Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1. Biochemical and Biophysical Research Communications 357(1): 295-301, 2007

Silencing of gene expression in cultured cells using small interfering RNAs. Current Protocols in Cell Biology Chapter 27: Unit 27.1.1-28, 2010

Evidence of transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells. Molecular Pharmacology 47(1): 51-56, 1995

Modulation of daunorubicin subcellular distribution in multidrug resistant MCF7 cells by SDZ-PSC833. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 593, 1997

Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs. Journal of Cellular Biochemistry 102(1): 75-81, 2007